

Supplementary table 1. Baseline characteristics of patients according to continue or discontinued of beta-blocker during index admission

Variable	Continue beta-blocker (n=433)	Discontinue beta-blocker (n=161)	P value
Age, years	75.3 ± 6.6	76.4 ± 6.9	0.08
Men, n (%)	233 (53.8)	92 (57.1)	0.516
BMI, kg/m ²	23.5 ± 3.6	22.4 ± 3.2	<0.001
Medical history			
Previous heart failure, n (%)	332 (76.7)	116 (72.0)	0.284
Hypertension, n (%)	336 (77.6)	117 (72.7)	0.233
Diabetes, n (%)	213 (49.2)	64 (39.8)	0.042
Atrial fibrillation, n (%)	151 (34.9)	46 (28.6)	0.170
COPD, n (%)	48 (11.1)	21 (13.0)	0.564
Myocardial infarction, n (%)	165 (38.1)	56 (34.8)	0.504
Medication on discharge			
RAS inhibitor, n (%)	316 (73.0)	107 (66.5)	0.127
MRA, n (%)	213 (49.2)	74 (46.0)	0.518
Loop diuretics, n (%)	71 (16.4)	49 (30.4)	<0.001
Digoxin, n (%)	300 (69.3)	116 (72.0)	0.546
Systolic BP on admission, mm Hg	135.5 ± 28.7	131.3 ± 29.0	0.116
Diastolic BP on admission, mm Hg	81.1 ± 18.0	76.8 ± 18.1	0.010
Heart rate on admission, beats/min	89.7 ± 23.8	92.9 ± 27.6	0.172
NYHA functional class III or IV on admission	380 (87.8)	153 (95.0)	0.009

Laboratory data on admission

eGFR, ml/min/1.73m ²	51.2 ± 25.1	46.7 ± 23.4	0.051
Sodium, mEq/L	137.7 ± 4.2	137.4 ± 5.0	0.454
Potassium, mEq/L	4.5 ± 0.7	4.5 ± 0.7	0.242
BNP, pg/mL	1593.1 ± 1306.1	1926.5 ± 1515.7	0.150
NT-pro-BNP, pg/mL	11545.9 ± 10872.8	14650.1 ± 12629.1	0.036
LVEF, %	29.1 ± 6.9	28.6 ± 7.8	0.483

BMI, body mass index; COPD, chronic obstructive pulmonary disease; RAS, renin angiotensin system; MRA, mineralocorticoid receptor antagonist; BP, blood pressure; GFR, glomerular filtration rate; BNP, brain natriuretic peptide; LVEF, left ventricular ejection fraction